Section Arrow
PHAR.NASDAQ
- Pharming Group NV
Quotes are at least 15-min delayed:2025/06/02 04:00 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
10.6 
1-M High
10.89 
Volume 
194 
Bid
11.39
Ask
11.63
Day Low
-- 
Open
-- 
1-M Low
8.3945 
Market Cap 
724.97M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.04 
20-SMA 9.7 
50-SMA 8.9 
52-W High 11.07 
52-W Low 6.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.21/0.03
Enterprise Value
830.09M
Balance Sheet
Book Value Per Share
3.13
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
297.20M
Operating Revenue Per Share
3.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/02 04:00 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib),a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.